Physician profile
Adrian S Long
NPI 1346407962
$4,796.71
in general payments reported to CMS, 2019-2025
33 companies · $698 in 2025
The $698 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $743 · 2021: $1,233 · 2022: $463 · 2023: $474 · 2024: $910 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,082.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,398.77 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $607.09 | 2021-2025 | |
| Optinose US, INC. | $292.81 | 2019-2024 | |
| Exact Sciences Corporation | $222.53 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $202.40 | 2021-2025 | Interstim |
| Astrazeneca Pharmaceuticals LP | $190.73 | 2019-2024 | Airsupra, Breztri |
| Lilly USA, LLC | $164.79 | 2019-2025 | Mounjaro, Zepbound |
| Ibsa Pharma INC. | $160.66 | 2019-2025 | Flector, Licart, Tirosint |
| Allergan, INC. | $160.25 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $149.50 | 2020-2025 | Spravato |
| Abbott Laboratories | $139.11 | 2019-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $127.57 | 2020-2021 | |
| Astellas Pharma US INC | $113.60 | 2023-2025 | Veozah |
| Pfizer INC. | $108.45 | 2023-2025 | |
| Glaxosmithkline, LLC. | $79.51 | 2020-2023 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $78.59 | 2024 | |
| Amneal Pharmaceuticals LLC | $61.36 | 2024-2025 | Unithroid |
| Tolmar, INC. | $57.15 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $52.28 | 2021 | |
| Alnylam Pharmaceuticals INC. | $50.96 | 2021-2022 | |
| Amgen INC. | $43.96 | 2023-2025 | Repatha, Otezla, Otezla |
| Otsuka America Pharmaceutical, INC. | $41.49 | 2025 | Rexulti |
| Acella Pharmaceuticals, LLC | $33.56 | 2024-2025 | NP Thyroid 60 |
| Axsome Therapeutics, INC. | $33.15 | 2025 | Auvelity |
| Eisai INC. | $33.08 | 2024 | |
| Horizon Therapeutics Plc | $32.75 | 2022-2023 | Krystexxa |
| Clarus Therapeutics INC. | $31.76 | 2021 | |
| Ucb, INC. | $27.40 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.28 | 2024 | Keveyis |
| Idorsia Pharmaceuticals US INC | $20.52 | 2023 | Quviviq |
| Kaleo, INC. | $19.29 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.06 | 2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.30 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.